These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22491959)

  • 1. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
    Stefanova N; Kaufmann WA; Humpel C; Poewe W; Wenning GK
    Acta Neuropathol; 2012 Jul; 124(1):51-65. PubMed ID: 22491959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies.
    Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N
    Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence.
    Kuzdas D; Stemberger S; Gaburro S; Stefanova N; Singewald N; Wenning GK
    Exp Neurol; 2013 Sep; 247():531-6. PubMed ID: 23399889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.
    Ubhi K; Rockenstein E; Mante M; Inglis C; Adame A; Patrick C; Whitney K; Masliah E
    J Neurosci; 2010 May; 30(18):6236-46. PubMed ID: 20445049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.
    Kaindlstorfer C; Sommer P; Georgievska B; Mather RJ; Kugler AR; Poewe W; Wenning GK; Stefanova N
    Neurotox Res; 2015 Oct; 28(3):185-94. PubMed ID: 26194617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein transgenic mice: relevance to multiple system atrophy.
    Fillon G; Kahle PJ
    Mov Disord; 2005 Aug; 20 Suppl 12():S64-6. PubMed ID: 16092093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.
    Laferrière F; He X; Zinghirino F; Doudnikoff E; Faggiani E; Meissner WG; Bezard E; De Giorgi F; Ichas F
    Cells; 2020 Oct; 9(11):. PubMed ID: 33138150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy.
    Sturm E; Fellner L; Krismer F; Poewe W; Wenning GK; Stefanova N
    Neurotherapeutics; 2016 Oct; 13(4):871-879. PubMed ID: 27259295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.
    Köllensperger M; Krismer F; Pallua A; Stefanova N; Poewe W; Wenning GK
    Mov Disord; 2011 Feb; 26(3):507-515. PubMed ID: 21462262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mouse model for investigating α-synuclein aggregates in oligodendrocytes: implications for the glial cytoplasmic inclusions in multiple system atrophy.
    Ishimoto T; Oono M; Kaji S; Ayaki T; Nishida K; Funakawa I; Maki T; Matsuzawa SI; Takahashi R; Yamakado H
    Mol Brain; 2024 May; 17(1):28. PubMed ID: 38790036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update.
    Jellinger KA; Lantos PL
    Acta Neuropathol; 2010 Jun; 119(6):657-67. PubMed ID: 20309568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.
    Shults CW; Rockenstein E; Crews L; Adame A; Mante M; Larrea G; Hashimoto M; Song D; Iwatsubo T; Tsuboi K; Masliah E
    J Neurosci; 2005 Nov; 25(46):10689-99. PubMed ID: 16291942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Multiple System Atrophy a Prion-like Disorder?
    Jellinger KA; Wenning GK; Stefanova N
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapidly progressive multiple system atrophy-cerebellar variant model presenting marked glial reactions with inflammation and spreading of α-synuclein oligomers and phosphorylated α-synuclein aggregates.
    Yamaguchi H; Nishimura Y; Matsuse D; Sekiya H; Masaki K; Tanaka T; Saiga T; Harada M; Kira YI; Dickson DW; Fujishima K; Matsuo E; Tanaka KF; Yamasaki R; Isobe N; Kira JI
    Brain Behav Immun; 2024 Oct; 121():122-141. PubMed ID: 38986725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of FABP7 by MF 6 counteracts cerebellum dysfunction in an experimental multiple system atrophy mouse model.
    Cheng A; Jia W; Finkelstein DI; Stefanova N; Wang H; Sasaki T; Kawahata I; Fukunaga K
    Acta Pharmacol Sin; 2024 Jan; 45(1):66-75. PubMed ID: 37605049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
    Ettle B; Kerman BE; Valera E; Gillmann C; Schlachetzki JC; Reiprich S; Büttner C; Ekici AB; Reis A; Wegner M; Bäuerle T; Riemenschneider MJ; Masliah E; Gage FH; Winkler J
    Acta Neuropathol; 2016 Jul; 132(1):59-75. PubMed ID: 27059609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.
    Kuzdas-Wood D; Fellner L; Premstaller M; Borm C; Bloem B; Kirik D; Wenning GK; Stefanova N
    BMC Neurosci; 2015 Dec; 16():86. PubMed ID: 26627686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder dysfunction in a transgenic mouse model of multiple system atrophy.
    Boudes M; Uvin P; Pinto S; Voets T; Fowler CJ; Wenning GK; De Ridder D; Stefanova N
    Mov Disord; 2013 Mar; 28(3):347-55. PubMed ID: 23426727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.
    Mavroeidi P; Arvanitaki F; Vetsi M; Becker S; Vlachakis D; Jensen PH; Stefanis L; Xilouri M
    Autophagy; 2022 Sep; 18(9):2104-2133. PubMed ID: 35000546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epsin2, a novel target for multiple system atrophy therapy via α-synuclein/FABP7 propagation.
    Cheng A; Kawahata I; Wang Y; Jia W; Wang H; Sekimori T; Chen Y; Suzuki H; Takeda A; Stefanova N; Finkelstein DI; Ma W; Chen M; Sasaki T; Fukunaga K
    Brain; 2023 Aug; 146(8):3172-3180. PubMed ID: 37082980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.